Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06179160 · ClinicalTrials.gov registry record · Phase 1

A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation

A Phase 1 study of Solid Tumors, sponsored by Incyte Corporation.

Recruiting
Registry status
Phase 1
Development phase
710
Enrollment target
20
Study locations

NCT06179160 is a Phase 1 study of Solid Tumors that is actively recruiting participants, run by Incyte Corporation. The registered enrollment target is 710 participants, above the 279-participant average among 125 other Solid Tumors trials with a reported enrollment target (154% higher). The trial reports 20 study locations across 15 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06179160, a Phase 1 study of Solid Tumors, is actively recruiting participants, sponsored by Incyte Corporation.

RECRUITING
Registry status
Phase 1
Development phase
710 participants
Enrollment target
20
Study locations

Study Summary

This study is conducted to determine the safety and tolerability of INCB161734 as a single agent or in combination with other anticancer therapies.

Conditions Studied

Solid Tumors

Interventions

  • DRUG Retifanlimab
  • DRUG Cetuximab
  • DRUG mFOLFIRINOX
  • DRUG INCB161734
  • DRUG GEMNabP

Study Locations (20)

California

  • Stanford University - Palo Alto
  • UCLA Healthcare Hematology-Oncology - Santa Monica

New York

  • Weill Cornell Medicine - New York
  • Memorial Sloan Kettering Cancer Center - New York

New South Wales

  • Chris Obrien Lifehouse - Camperdown
  • St Vincent'S Hospital Sydney - Darlinghurst

Victoria

  • The Alfred Hospital - Melbourne
  • Peter Maccallum Cancer Centre - North Melbourne

Other

  • Cliniques Universitaires Ucl Saint-Luc - Brussels
  • Universitair Ziekenhuis Antwerpen (Uza) - Edegem

Arizona

  • Mayo Clinic Hospital - Phoenix

Colorado

  • Sarah Cannon Research Institue At Healthone - Denver

Florida

  • Florida Cancer Specialists - Sarasota

Trial Details

FieldValue
Enrollment Target 710 participants
Start Date 2024-01-04
Est. Completion 2027-01-01
Phase Phase 1

Sponsor

Incyte Corporation

239 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06179160

The ClinicalTrials.gov registry entry for NCT06179160 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 710 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 279-participant average among 125 other Solid Tumors trials with a reported enrollment target (154% higher). The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Solid Tumors appearing as the primary indexed condition, and to 5 interventions - of which Retifanlimab is the first listed.

NCT06179160 reports 20 study locations spanning 15 distinct geographic areas - top geographies include California, New York, New South Wales.

Frequently Asked Questions

What is clinical trial NCT06179160 about?

NCT06179160 is a clinical study titled "A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation". This study is conducted to determine the safety and tolerability of INCB161734 as a single agent or in combination with other anticancer therapies.

What is the current status of trial NCT06179160?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 710 participants. The study started on 2024-01-04. Estimated completion is 2027-01-01.

What conditions does trial NCT06179160 study?

This clinical trial studies the following conditions: Solid Tumors.

What interventions are being tested in trial NCT06179160?

The interventions under investigation include: Retifanlimab (DRUG), Cetuximab (DRUG), mFOLFIRINOX (DRUG), INCB161734 (DRUG), GEMNabP (DRUG).

Who is sponsoring clinical trial NCT06179160?

This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06179160 being conducted?

This trial has 20 study locations across Arizona, California, Colorado, Florida, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Solid Tumors

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Solid Tumors

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.